Nuveen Asset Management, LLC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 191 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q1 2024$494,248
+23.4%
737,4640.0%0.00%
Q4 2023$400,665
-6.8%
737,464
+2.9%
0.00%
Q3 2023$429,774
-54.0%
716,528
-0.4%
0.00%
Q2 2023$935,094
+38286.5%
719,303
-48.0%
0.00%
-100.0%
Q1 2023$2,436
-76.7%
1,383,629
-58.5%
0.00%
-75.0%
Q4 2022$10,464
-99.9%
3,332,601
-0.7%
0.00%
-42.9%
Q3 2022$16,444,000
+265.0%
3,355,829
+208.4%
0.01%
+250.0%
Q2 2022$4,505,000
-36.7%
1,088,197
-11.7%
0.00%0.0%
Q1 2022$7,122,000
-23.1%
1,232,207
-5.0%
0.00%
-33.3%
Q4 2021$9,260,000
-32.4%
1,296,866
-9.6%
0.00%
-25.0%
Q3 2021$13,700,000
-18.2%
1,434,525
+2.6%
0.00%
-20.0%
Q2 2021$16,740,000
-8.4%
1,398,446
-4.1%
0.01%
-16.7%
Q1 2021$18,273,000
-18.7%
1,458,349
+1.3%
0.01%
-25.0%
Q4 2020$22,475,000
+74.0%
1,440,260
+5.4%
0.01%
+60.0%
Q3 2020$12,914,000
+104.9%
1,366,511
+94.2%
0.01%
+66.7%
Q2 2020$6,304,000
+46.1%
703,636
+3.9%
0.00%
+50.0%
Q1 2020$4,314,000
-33.3%
677,266
-12.4%
0.00%0.0%
Q4 2019$6,468,000
-3.5%
772,848
+4.4%
0.00%
-33.3%
Q3 2019$6,701,000
-21.3%
740,511
-6.3%
0.00%0.0%
Q2 2019$8,516,000790,6820.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Rokos Capital Management LLP 6,474,348$11,394,8520.84%
WASATCH ADVISORS LP 13,642,417$24,010,6540.15%
Avidity Partners Management LP 2,470,000$4,347,2000.14%
Acrisure Capital Management, LLC 75,832$133,4640.14%
Golden State Equity Partners 135,765$238,9460.13%
Long Focus Capital Management, LLC 1,072,000$1,886,7200.11%
KLK CAPITAL MANAGEMENT LLC 44,323$78,0080.10%
CAXTON ASSOCIATES LP 288,218$507,2640.08%
XTX Topco Ltd 206,334$363,1480.08%
Rhenman & Partners Asset Management AB 314,157$534,0670.06%
View complete list of SANGAMO THERAPEUTICS INC shareholders